HK1084150A1 - Polypeptide having an improved cytosine deaminase activity - Google Patents

Polypeptide having an improved cytosine deaminase activity

Info

Publication number
HK1084150A1
HK1084150A1 HK06106361A HK06106361A HK1084150A1 HK 1084150 A1 HK1084150 A1 HK 1084150A1 HK 06106361 A HK06106361 A HK 06106361A HK 06106361 A HK06106361 A HK 06106361A HK 1084150 A1 HK1084150 A1 HK 1084150A1
Authority
HK
Hong Kong
Prior art keywords
polypeptide
cytosine deaminase
deaminase activity
improved
activity
Prior art date
Application number
HK06106361A
Other languages
English (en)
Inventor
Erbs Philippe
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Priority to HK08107021.0A priority Critical patent/HK1112024A1/xx
Publication of HK1084150A1 publication Critical patent/HK1084150A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06106361A 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity HK1084150A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK08107021.0A HK1112024A1 (en) 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06
PCT/IB2004/002505 WO2005007857A1 (en) 2003-07-21 2004-06-29 Polypeptide having an improved cytosine deaminase activity

Publications (1)

Publication Number Publication Date
HK1084150A1 true HK1084150A1 (en) 2006-07-21

Family

ID=39719832

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08107021.0A HK1112024A1 (en) 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity
HK06106361A HK1084150A1 (en) 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK08107021.0A HK1112024A1 (en) 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity

Country Status (17)

Country Link
US (3) US7790445B2 (el)
EP (2) EP1897938B9 (el)
JP (1) JP4672659B2 (el)
KR (1) KR101062140B1 (el)
CN (1) CN1826410B (el)
AT (1) ATE405654T1 (el)
AU (1) AU2004257935B2 (el)
CA (1) CA2532783C (el)
CY (1) CY1110397T1 (el)
DE (1) DE602004015995D1 (el)
DK (1) DK1649023T3 (el)
ES (1) ES2311831T3 (el)
HK (2) HK1112024A1 (el)
IL (1) IL173158A (el)
PL (1) PL1649023T3 (el)
PT (1) PT1649023E (el)
WO (1) WO2005007857A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
TWI614342B (zh) 2007-07-03 2018-02-11 存斯精菱公司 禽類永生化細胞系
CN105274125A (zh) * 2008-09-26 2016-01-27 托卡根公司 基因治疗载体和胞嘧啶脱氨酶
EP2429580A1 (en) 2009-05-12 2012-03-21 Transgene SA Method for orthopoxvirus production and purification
JP2012533311A (ja) 2009-07-21 2012-12-27 トランジェーヌ、ソシエテ、アノニム ニワトリ胚消化のための酵素組成物
EP2527432A1 (en) * 2011-05-23 2012-11-28 Novozymes A/S Bi-directional cytosine deaminase-encoding selection marker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
ES2768715T3 (es) 2014-04-10 2020-06-23 Transgene Vectores oncolíticos poxvíricos
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2016128542A1 (en) * 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2019170820A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JP7484717B2 (ja) 2018-09-26 2024-05-16 アステラス製薬株式会社 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
EP0931830B1 (en) 1993-02-16 2001-03-07 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and phophylaxis of neoplasia
AU6953394A (en) * 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) * 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
PT1649023E (pt) 2008-11-20
WO2005007857A1 (en) 2005-01-27
US20070264235A1 (en) 2007-11-15
JP4672659B2 (ja) 2011-04-20
EP1897938B1 (en) 2010-10-06
EP1649023B1 (en) 2008-08-20
KR101062140B1 (ko) 2011-09-05
ATE405654T1 (de) 2008-09-15
EP1897938A1 (en) 2008-03-12
CA2532783A1 (en) 2005-01-27
US20100330051A1 (en) 2010-12-30
CA2532783C (en) 2013-09-17
JP2006527994A (ja) 2006-12-14
AU2004257935B2 (en) 2009-11-19
DK1649023T3 (da) 2008-10-06
CY1110397T1 (el) 2015-04-29
US20100330031A1 (en) 2010-12-30
IL173158A (en) 2009-12-24
KR20060040697A (ko) 2006-05-10
AU2004257935A1 (en) 2005-01-27
US7790445B2 (en) 2010-09-07
US8257692B2 (en) 2012-09-04
PL1649023T3 (pl) 2009-01-30
CN1826410B (zh) 2011-10-26
CN1826410A (zh) 2006-08-30
EP1897938B9 (en) 2011-08-31
EP1649023A1 (en) 2006-04-26
US8226954B2 (en) 2012-07-24
HK1112024A1 (en) 2008-08-22
ES2311831T3 (es) 2009-02-16
IL173158A0 (en) 2006-06-11
DE602004015995D1 (de) 2008-10-02

Similar Documents

Publication Publication Date Title
HK1084150A1 (en) Polypeptide having an improved cytosine deaminase activity
IN2014CN02050A (el)
EP1801206A4 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
BR0308946A (pt) Gene que codifica a acetolactato sintase
ATE342917T1 (de) Antimikrobielle polypeptide aus pseudoplectania nigrella
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
DK1601776T3 (da) Ekspressionsvektorer omfattende mCmV-IE2-promotoren
GB0711424D0 (en) Recombinant transferrin mutants
TW200734350A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2003014350A1 (fr) Nouveau gene de riz regulant la tolerance au stress salin
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
TW200510460A (en) Antimicrobial polypeptides
ATE414156T1 (de) Lipase-varianten
ATE496121T1 (de) Lactobacillus fermentum n-desoxyribosyl- transferasen und deren verwendung zur enzymatischen synthese von 2',3'- didesoxynucleosiden und 2',3'-didehydro-2',3'- didesoxynucleosiden
HK1082510A1 (en) Promoter to il-18bp, its preparation and use
WO2003072733A3 (en) Modified bace
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
DE60330140D1 (de) Gen-silencing-vektor und diesen verwendendes gen-silencing-verfahren
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
TW200716666A (en) Isolated photoprotein gr-bolinopsin, and its use
AU2003258723A8 (en) Use of the protein maba (fabg1) of less thanigreater thanmycobacterium tuberculosisless than/igreater than for designing and screening antibiotics
WO2009004967A1 (ja) エンドグリコセラミダーゼｉ遺伝子
EP1854485A4 (en) PREVENTION AGENTS / REMEDIES AGAINST CANCER